AXGT Axovant Gene Therapies Ltd.

3.19
-0.12  -4%
Previous Close 3.31
Open 3.3
Price To Book 24.54
Market Cap 126,088,894
Shares 39,526,299
Volume 142,028
Short Ratio
Av. Daily Volume 163,616
Stock charts supplied by TradingView

NewsSee all news

  1. Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

    NEW YORK and BASEL, Switzerland, May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

  2. Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

    NEW YORK and BASEL, Switzerland, May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

  3. Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

    NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had

  4. Axovant Provides Business and Operations Update During the COVID-19 Pandemic

  5. Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    NEW YORK and BASEL, Switzerland, March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 6-month data from second dose cohort due by 4Q 2020
AXO-Lenti-PD - SUNRISE-PD
Parkinson's disease
Phase 1 data presented October 23, 2019.
AXO-AAV-GM2
GM2 gangliosidosis
Phase 1 six-month data from Part A in juvenile (Type II) GM1 gangliosidosis due by YE 2020.
AXO-AAV-GM1
GM1 gangliosidosis

Latest News

  1. Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

    NEW YORK and BASEL, Switzerland, May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

  2. Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

    NEW YORK and BASEL, Switzerland, May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

  3. Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

    NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had

  4. Axovant Provides Business and Operations Update During the COVID-19 Pandemic

  5. Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    NEW YORK and BASEL, Switzerland, March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

  6. Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of

  7. Axovant Gene Therapies Announces Pricing of $65 Million Public Offering

    NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its

  8. Axovant Gene Therapies Announces Commencement of Public Offering

    NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common

  9. Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019

    NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies, today provided financial results for its

  10. Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs

    NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced

  11. Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis

    NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1

  12. Axovant Announces Amendment to Credit Facility with Hercules Capital

    NEW YORK and BASEL, Switzerland, Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only period for 9 monthsDebt

  13. Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis

    NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug

  14. Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019

    First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued enrollment of patients in AXO-AAV-GM1 registrational study, with

  15. Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019

    NEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D.,

  16. Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress

    NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies, today announced upcoming presentations

  17. Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa

    BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani, Pharm.D., senior vice